Drug Discovery & Development Highlights: Albumin Technology, Liver Toxicity, AIDS Vaccine and Personalized Medicine

Read about what has been happening in the Drug Discovery & Development community this month:

Exclusive Interview: Dr Darrell Sleep Talks to SelectScience about Albumin and its Power to Boost Existing Drugs
SelectScience interviewed Dr Darrell Sleep from Novozymes BioPharma about this revolutionary new albumin based technology and the benefits to the Drug Discovery & Development industry.

Metabolic Phenotyping: New Tool for Drug Response Prediction and Personalized Medicine
Learn how metabolic phenotyping using a mass spectrometry platform could support diagnosis and disease prediction as well as the prognosis of the potential of a certain therapy by two examples from Alzheimer´s disease research.

Scalable Protein Production Using Flow Electroporation
A great review of case studies using MaxCyte transfection, including cell type flexibility, scalability, consistency, and high-yield protein production, that makes this an ideal TGE platform for use in early-phase candidate identification as well as for generating the gram-level antibody quantities needed for late-stage pharmacology formulation, stability, and process and purification development.

HepatoPac™: A Bioengineered Micro-Liver Platform for Predictive Drug Metabolism and Toxicity Studies
A human liver model with precise microscale cyto-architecture and optimal stromal interactions (HepatoPac™) that displays high levels of liver‐specific functions for several weeks in vitro and has been shown to improve the predictions of clinical outcomes as compared to traditional approaches.

SelectScience Wins UK Life Science Employer of the Year Award 2014
SelectScience, has been recognized in the UK Life Science Skills Award scheme. The scheme rewards apprentices, individuals and employers who have excelled in contributing to the development of skills within the life science sector.

Scripps Research Institute Scientists Show AIDS Vaccine Could Work Against Changeable Site on HIV
The finding, from a study led by scientists at The Scripps Research Institute (TSRI), is likely to influence future designs for HIV vaccines and antibody-based therapies.